Resources & Guides

Complete GLP-3 retatrutide dosage guide covering the 2mg to 12mg weekly titration protocol, printable dosing chart, half-life pharmacokinetics, weight loss results from clinical trials, side effects management, and a free interactive dosing calculator.

Everything you need to know about tirzepatide dosing: dual-agonist mechanism, clinical trial efficacy data, starting dose through maintenance, titration schedules, half-life pharmacokinetics, side effects, and dosing calculator.

The definitive guide to retatrutide (reta) pharmacokinetics: approximately 6 days half-life per NEJM Phase 2 data, 30-day full clearance, and 4-5 week steady state per dose level. Includes half-life comparison to tirzepatide and semaglutide, dosing implications, and FAQ.

Split dosing semaglutide twice weekly takes the same total weekly dose and divides it into two injections about 3 to 4 days apart. Every semaglutide product is FDA-approved for once-weekly dosing only, so this is off-label. Here is the pharmacokinetic reasoning, the pen-mechanics problem, and what has never been tested.

Technical overview of the pharmacokinetic model behind GLP3Planner. Covers the one-compartment model with first-order absorption, the Bateman equation, drug parameters sourced from clinical trials, multi-dose superposition and steady state, the reconstitution math (BAC water to syringe units), and the standard per-compound titration ladders.

Semaglutide mimics a natural gut hormone to reduce hunger, slow digestion, and signal the brain to stop eating. This article explains exactly how each mechanism works and why the weekly injection lasts all week.

A twice-weekly retatrutide split takes the same total weekly dose and divides it into two injections about 3 to 4 days apart. The 6-day half-life is what makes that spacing logical. Here is the pharmacokinetic reasoning, the practical mechanics, and the honest evidence picture.

While retatrutide is designed for weekly dosing, emerging interest in microdosing raises questions about splitting doses to optimize tolerability and efficacy. We examine the science, community experiences, and critical considerations.

How retatrutide drug levels build week over week toward steady-state plateau. A model-derived accumulation chart per dose level, why the 4-week titration hold matches the pharmacokinetics, and the practical implications for evaluating each dose.

A practical how-to guide for running a GLP-1 microdosing protocol on semaglutide or tirzepatide, plus why retatrutide has no lawful microdosing route. Covers approach selection, compound-specific steps, titration decisions, and calculator modeling.

A comprehensive comparison of GLP-1 dose calculators and plotters, examining features, drug support, and which tool best fits your medication tracking needs.

Zepbound contains tirzepatide, a dual agonist that activates both GLP-1 and GIP receptors simultaneously. Here is exactly what happens in your body, what SURMOUNT-1 showed at 72 weeks, and why the 5-day half-life matters for your dose schedule.

Dive deep into pharmacokinetic principles, from basic half-life concepts to complex compartmental models, and understand how individual factors affect drug concentrations.

Everything you need to know about semaglutide dosing: GLP-1 mechanism, clinical trial efficacy data, starting dose through maintenance, titration schedules, half-life pharmacokinetics, side effects, and how to use a dosing calculator.

While semaglutide is designed for weekly dosing, its 7-day half-life makes it uniquely suited for split dosing exploration. We examine the pharmacokinetics, protocols, and considerations for microdosing Ozempic and Wegovy.

While tirzepatide is designed for weekly dosing, emerging interest in microdosing raises questions about splitting doses to optimize tolerability and efficacy. We examine the science, community experiences, and critical considerations.